Overview

A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
A Phase I Study of CC-5013 in combination with Doxil, Vincristine and Decadron (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma
Phase:
Phase 1
Details
Lead Sponsor:
Celgene Corporation
Treatments:
Lenalidomide
Thalidomide